– Postponement of at least 2 years of the final maturity of all bank loans
– Equitization of the loan taken out from the EIB to limit its repayment in cash and optimize the Company’s cash flow
Paris, March 22, 2024 – 5:45 p.m. (CET)
CARMAT (FR0010907956, ALCAR, PEA-PME eligible), designer and developer of the most advanced total artificial heart in the world, aiming to offer a therapeutic alternative to patients suffering from advanced biventricular heart failure (the “Company” or “CARMAT”) , today announces a final agreement with all of its financial creditors on new repayment terms for its bank loans.
To receive all CARMAT financial information in real time, request it by email to [email protected]. Your registration will be immediate.